Real-World Evidence

Unlocking New Possibilities for Pharma with our Lung Cancer datasets.

Our granular and quality-controlled real-world dataset allows in-depth analysis and research into the CLL patient journey.

67% stage I-II breast cancer patients, 14% stage III-IV breast cancer patients - discover more LynxCare datasets insights.

Gain fresh insights into the relationship of specific comorbidities, adverse events and biomarkers with immuno-oncology prognosis through LynxCare's European data asset.

We are proud to share that we have successfully renewed our ISO 27001 and NEN 7510 certifications. These certifications are not just badges, but a reflection of our commitment to maintaining the highest information security standards in healthcare!

LynxCare's comprehensive datasets within its European hospital network offer fresh insights into Immuno-Oncology, Breast Cancer, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM), including comorbidity factors, treatment patterns, and staging.

LynxCare's comprehensive data asset offers fresh insights into breast cancer, including comorbidity factors, treatment patterns, and staging. With over 4800 estimated patients and 598 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of breast cancer patients, empowering clinicians to make informed decisions.

With over 7400 estimated patients and 610 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of lung cancer patients, empowering clinicians to make informed decisions.

“We are thrilled to embark on this partnership journey with Keyrus Life Science and are proud to have already set the first successful steps in France, with new geographies on our horizon,” says Georges De Feu, CEO LynxCare.